ABSTRACT. We have evaluated the effects of the combined administration of Galanin (Gal) plus growth hormone-releasing hormone (GHRH) and of pyridostigmine (PD), a cholinergic agonist, plus Gal on G H secretion in 1 5 children (12 males and three females, age 7.7-14.5 y) with short stature. Children were subdivided into two groups. In group 1 (n = 7) Gal (15 pg/kg h i.v.) plus GHRH (1 pg/kg i.v.) administration induced a higher G H rise (peak = 73.1 f 10.2 ng/mL, mean 2 SD, area under the curve (AUC) = 531.9 +: 78.7 ng.min.mL-') than did GHRH alone (peak = 38.9 f 26.5 ng/mL, p < 0.05; AUC = 256.9 f 165.6 ng/mL/min-', p < 0.005). Gal had a synergistic effect on the GHRH-induced G H response because the GHRH plus Gal AUC response was significantly higher ( p < 0.01) than the sum of the areas of response to GHRH and Gal alone. In group 2 (n = 8) P D administration (60 mg/kg p.0.) had no significant effects on the Gal-induced G H secretion (peak = 14.9 f 8.8 and 16.0 f 9.8 ng/mL after Gal and P D + Gal, respectively; AUC = 91.2 f 52.1 and 125.2 + 83.6 n g m L m i n -' after Gal and P D + Gal, respectively). Our results confirm the ability of Gal to stimulate G H secretion in children, and strengthen the view that its mechanism of action involves modulation of endogenous somatostatin release. (Pediatr Res 27: 405-407,1990) 
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The cholinergic system plays a fundamental role in the control of G H secretion in man (10) . Anticholinergic drugs blunt the GH response to a variety of stimuli, including GHRH. Conversely, administration of cholinergic agonist drugs enhances the G H response to GHRH in both adults and children (lo), and restores GH secretion after intermittent administration of GHRH (10) as well as in conditions of suppressed G H secretion such as obesity (1 1) and hyperglycemia (12) . Studies in animals have shown that the mechanism by which cholinergic compounds exert their neuroendocrine effects is via inhibition of endogenous SRIF release (1 3).
Interestingly, Gal has been shown to abolish the inhibitory effect of cholinergic blockade on the GHRH-induced GH secretion in man (14) . Moreover, cholinergic antagonists inhibit the GH release induced by Gal (1 5) .
In this study we evaluated whether Gal is able to potentiate the GHRH-induced GH release in children, and whether administration of a cholinergic agonist drug, PD, would affect the GH response to Gal.
MATERIALS AND METHODS
Fifteen children (12 males and three females) aged 7.7-14.5 y were studied. All children were undergoing clinical and laboratory evaluations for their short stature, and were ultimately found to have constitutional growth delay and/or familial short stature. All had a stature below the 3rd percentile for age, and a GH response to stimulation >7.0 ng/mL. All children were prepubertal except for case 8 of Table 2 who was in Tanner 2 stage of sexual maturation. None had taken long-term medication before the study. The studies were canied out under institutionally approved protocols, and informed consent was obtained from the children or from their legal guardians.
Children were randomly assigned to two groups. Children of group 1 (n = 7) were tested on three occasions with 1 ) GHRH 1-29 at the dose of 1 Fg/kg i.v.; 2) Gal (synthetic porcine, Inalco, Milan, Italy) infused at the dose of 15 ~g/kg/h for 1 h, as previously described (9); 3) Gal plus GHRH; GHRH was administered as above at the start of Gal infusion (time 0). Blood samples were drawn from an indwelling catheter inserted in an antecubital vein at times -60, -30, 0, 15, 30, 60, 90, and 120 min. responses to GHRH and Gal plus GHRH and to Gal and PD plus Gal. All values are given as mean + SD.
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Fig. 1. Plasma growth hormone (GH) levels after GHRH (a), Gal
(W), and GHRH plus Gal (A) in a representative child (case 2, Table 1 ).
was administered orally at time -60 and Gal infusion started at time 0. Blood samples were drawn as in group 1.
In both studies the experiments were carried out in random order with an interval of 3-5 d. All experiments started between 0800 and 0900 h after the children fasted overnight.
GH was measured by double antibody RIA using reagents provided by CEA-IRE Sorin (Italy). The sensitivity of the assay was 0.2 ng/mL with an intra-and interassay coefiicient of variation of 4.5 and 7.9%, respectively.
All values are expressed as peak GH levels or AUC calculated by trapezoidal integration. Statistical analysis of the results was carried out by means of analysis of variance for repeated measures. Paired t test was used to compare GH peak and AUC
RESULTS
Gal administration was well tolerated and apart from a bitter taste in the mouth did not induce noticeable side effects either alone or in combination with PD or GHRH.
Group I. In all children GHRH administration evoked a prompt clear-cut rise of GH levels from basal values (1.4 k 1.0 ng/mL) to peak values of 38.9 k 26.5 ng/mL (AUC = 256.9 k 165.6 ng. mL. min-I) ( Table I) . After Gal infusion GH levels rose to 8.8 + 3.5 ng/mL (AUC = 64.4 + 14.4 ng.mL.min-I) (Table 1) . Gal significantly enhanced the GH response to GHRH, evaluated either as peak (73.1 + 10.2 ng/mL, p < 0.05) or AUC (531.9 + 78.7 ng.mL.min-I, p < 0.005) ( Table 1) .
Gal had a synergistic effect on the GHRH-induced GH response, since the GHRH plus Gal AUC response was significantly higher ( p < 0.01 by paired t test) than the sum of the areas of response to GHRH and Gal alone. The plasma GH response to GHRH, Gal, and GHRH plus Gal in a representative case is shown in Figure 1 .
Group 2. Peak GH levels after Gal infusion were 14.9 + 8.8 ng/mL (AUC = 9 1.2 f 52.1 ng . m L min-') ( Table 2) . Peak GH levels after PD administration were 14.3 + 7.0 ng/mL (AUC = 97.9 + 48.3 n~.mL.rnin-') ( Table 2) . Pretreatment with PD caused no signkcant effects on the ~al-induced GH response evaluated either as peak (16.0 f 9.8 ng/mL) or AUC (125.2 + 83.6 n g min. mL-I) ( Table 2 ). The plasma GH response to PD, Gal, and PD + Gal in a representative case is shown in Figure   2 .
DISCUSSION
Our study confirms the ability of Gal to stimulate GH secretion in children with short stature (9) . We have also shown that Gal enhances the GH response to GHRH, confirming previous findings in adults (8) . Inasmuch as Gal has been shown to have no direct effects on the pituitary (5), it is conceivable that its effect on GH secretion are mediated by a reduction of endogenous SRIF release. This hypothesis is further supported by the finding of this study that PD had no effects on the Gal-induced GH secretion.
PD is a cholinergic agonist drug that enhances cholinergic neurotransmission by inhibiting cholinesterases. A large body of evidence indicates that the mechanism by which cholinergic compounds affect GH secretion in humans is via modulation of hypothalamic SRIF release (10) . Had the Gal-induced GH secre- * Abbreviations as in Table 1 . Fig. 2 . Plasma growth hormone (GH) levels after pyridostigmine (e), G a l (B), a n d PD plus G a l (A) in a representative child (case 3, Table 2 ).
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tion been due to stimulation of endogenous GHRH release, one would have expected a higher response to Gal plus PD versus
